Skip to Main Content
Introduction

Sarcoidosis is a granulomatous disease with an incidence of up to 18 in 100,000 in some populations. Symptoms range from asymptomatic benign lesions to organ failure, with up to 90% of patients presenting with lung involvement. Sarcoidosis is often a diagnosis of exclusion: inflammation, lymphadenopathy, and sterile granulomata without an identifiable cause. Granuloma formation occurs in primary immunodeficiencies, but the full landscape of these deficiencies and their association with sarcoid is not fully understood.

Results

We looked retrospectively at patients initially diagnosed with sarcoidosis referred to the National Institutes of Health (NIH). Many people had refractory inflammation or had a diagnosis of sarcoidosis in the setting of other immune dysfunction such as common variable immunodeficiency (CVID). Within this group of 37 patients with completed whole-genome or whole-exome sequencing, 22 had pathogenic variants, likely pathogenic variants, or variants of unknown significance in relevant candidate genes including SP110, GATA2, NFKBIA, NFKB1, IRF8, CTLA-4, NCF1, SLC26A9, RFX5, MEFV, GFI1, PLCG2, STAT1, BACH2, IKZF3, JAK1, ADCY10, and STXBP2.

Conclusion

This study highlights the diseases often gathered under the diagnosis “sarcoid”. Prior studies have highlighted immune dysregulation within multiple pathways, including the interferon-gamma (IFN-γ) response pathway (GATA2, STAT1, NFKBIA, and IRF8), Th17.1 signaling (STAT1 and IRF8), and inflammasome response (IRF8, MEFV, and PLCG2), as being important in granuloma formation. Numerous mutations within this cohort have previously been associated with common immunodeficiencies (RFX5, NFKBIA, SP110, and IKZF3) or predominant antibody deficiencies (NFKB1). This cohort also showed defects of phagocyte number or function (GFI1, NCF1, and GATA2). Within this study, two variants were identified that are not associated with immunodeficiencies, including SLC26A9, an ion transporter for chloride previously identified in atypical cystic fibrosis, and ADCY10, a catalyst for the formation of cAMP. Though it is possible that some of these variants may not be causal or even relevant to the formation of granulomas, this cohort shows how some patients presenting with lymphadenopathy and sterile granulomata in various organs were identified to have Mendelian traits underlying their diagnoses of sarcoidosis.

Table 1.
Subject IDGenetic Defect IdentifiedAllele Frequency gnomAD v4.1.0Classification (ClinVar)ZygosityCADD ScoreInheritance PatternOrgan InvolvementInfection History
1NFKBIA (IkBa) (c.691G>T, p.Asp231Tyr)4.7e-5VUSHet27.3ADCNS, Exocrine, CutaneousNTM, EBV
2CTLA4 (c.567+5G>C)0PathogenicHet26ADOcular, LN, Cutaneous, Pulmonary 
3No defect identified     Ocular, Cutaneous, PulmonaryEBV
4NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs)8.5e-4PathologicHomo35ARPulmonary, Exocrine, LNS. capitis
5No defect identified     CutaneousSphingomonas paucimobilis
6No defect identified     PulmonaryM. avium
8No defect identified     Pulmonary, Neuro, LNJCV
9No defect identified     Pulmonarydisseminated M. tilbergii
11NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs)8.5e-4PathologicHomo38ARPulmonary 
12NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs)8.5e-4PathologicHomo38ARMSK, Ocular, SplenicA. fumigatus
141q41 222762100-224070013  Het  Hepatic, PulmonaryS. pneumo
1.308 Mb-1.636 Mb Loss
IFIH1
NOD2
LRBA
FAT4
KMT2D
15SP110 (c.1428_1429del, p.Tyr476Ter)1.8e-6Not ReportedHet34ARCutaneousM. chelonae
16SLC26A9 (c.1459G>A, p.Ala487Thr)6.9e-5Not ReportedHet20.8 PulmonaryMAC
17GATA2 (c.1021_1024dup, p.Ala342GlyfsTer43)0PathologicHetNAADPulmonary 
18No defect identified     Pulmonary, Cutaneous 
19IRF8 (c. 536C>T, p.Ala179Val)6.5e-6VUSHet17.54AR/ADNeuroMAC
20No defect identified     Pulmonary, GIMAC
23GATA2 (c.1021_1024dup, p.Ala342GlyTer43)0PathogenicHetNAADBM 
25STXBP2 (c.1001 C>T, p.Pro334Leu)4e-5Likely pathogenicHomo29.9ARHepatic 
26No defect identified     Pulmonary 
27No defect identified     Pulmonary 
28NFKB1 (c.1513A>C, p.Lys505Gln)6.85e-7VUSHet26.2ADPulmonary, Cardiac 
29RFX5 (c.353+2T>G)1.8e-4Likely pathogenicHet33ARPulmonary, Cutaneous 
30IKZF3 (c.244G>A, p.Glu82Lys)1.4e-4VUSHet23.6ADHepatic, OcularRecurrent Pneumonia
31No defect identified     PulmonaryEBV
32No defect identified     Cardiac 
33No defect identified     NeuroVZV
34MEFV (c.289C>A, p.Gln97Lys)9.43e-5VUSHet9.8AD/ARPulmonary, Hepatic 
35GFI1 (c.200G>A, p.Arg67Lys)3.4e-5VUSHet21.2ARPulmonaryAspergillus, pneumocystis
36PLCG2 (c.2931C>G, p.Tyr977Ter)6.19e-7VUSHet38ADPulmonary, Splenic, CutaneousRecurrent sinusitis
37STAT1 (c.736G>A, p.Ala246Thr)0VUSHet24ADPulmonaryHistoplasmosis
38BACH2 (c.2327 C>T, p.Pro776Leu)1.8e-5VUSHet16.9ADPulmonary 
39No defect identified     Pulmonary 
40ADCY10 (c.4477del, p.Leu1493SerfsTer24)3e-4PathogenicHet33ADPulmonary 
41No defect identified     Pulmonary 
42No defect identified     Cardiac 
43JAK1 (c.1078C>T, p.Arg360Trp)5.9e-5VUSHet25.1AD/ART1DM, Pulmonary, OcularHistoplasmosis

This abstract is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by-nc-nd/4.0/).

or Create an Account

Close Modal
Close Modal